Brief: Specialised Therapeutics Signs Partnership Agreement With Akeso, CTTQ-Akeso To Commercialise New Anti-PD1 Antibody In Australia And Southeast Asia
11/04/2023 23:02
April 11 (Reuters) - Akeso Inc 9926.HK :
* SPECIALISED THERAPEUTICS SIGNS PARTNERSHIP AGREEMENT WITH
AKESO,
CTTQ-AKESO TO COMMERCIALISE NEW ANTI-PD1 ANTIBODY IN AUSTRALIA
AND SOUTHEAST ASIA
Source text for Eikon: ID:nPn9X7CSZa
Further company coverage: 9926.HK
((Reuters.Brief@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals